Blythe Adamson, PhD, MPH
New York, New York, United States
5K followers
500+ connections
About
comparing the effectiveness of drugs and policies to accelerate research and improve…
Activity
-
We are introducing a new section called “Methods Explained” in the July/August 2024 issue of Value & Outcomes Spotlight. In these bite-sized columns,…
We are introducing a new section called “Methods Explained” in the July/August 2024 issue of Value & Outcomes Spotlight. In these bite-sized columns,…
Liked by Blythe Adamson, PhD, MPH
-
It has been ~10 weeks since I left #Flatiron to focus on my ailing parents. I’ve spent a lot of quality time with them (and still am) as well as some…
It has been ~10 weeks since I left #Flatiron to focus on my ailing parents. I’ve spent a lot of quality time with them (and still am) as well as some…
Liked by Blythe Adamson, PhD, MPH
Experience
Education
-
University of Washington
Activities and Societies: Mary Gates Research Grant Scholar, Fred Hutch Infectious Diseases Research Scholar
Honors Thesis: "Escape Mutations in HIV-1 Elite Suppressors"
-
Master Thesis: "Predictors of HIV Vaccine Immunogenicity in HVTN 204”
-
Activities and Societies: The Comparative Health Outcomes, Policy, & Economics (CHOICE) Institute, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Society for Medical Decision Making (SMDM), and Academy Health
Doctoral Dissertation: "Biomedical Strategies for HIV Prevention"
Licenses & Certifications
Publications
-
Assessment tool for establishing local pharmaceutical manufacturing in low- and middle-income countries
International Journal of Pharmacy Practice
This tool is intended to identify barriers and facilitators for local manufacturing and provide a roadmap for decision‐making across multiple stakeholders. A case study in Namibia identified key barriers and facilitators to successful manufacturing in that county.
Other authorsSee publication -
Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study
Scientific Reports
Results suggest that a partially effective HIV vaccine will have substantial impact on the HIV epidemic in South Africa and offer good value if priced less than $105 for a five-dose series. Vaccination campaigns every two years may offer greater value for money than continuous vaccination reaching the same coverage level.
-
The Good, the Bad, and the Ugly: Reminders About Propensity Scores
Value and Outcomes Spotlight
-
The Potential Cost‑Effectiveness of Pre-exposure Prophylaxis Combined with HIV Vaccines in the United States
Vaccines
This economic evaluation aims to support policy-making on the combined use of pre-exposure prophylaxis (PrEP) with HIV vaccines in development by evaluating the potential cost-effectiveness of implementation that would support the design of clinical trials for the assessment of combined product safety and efficacy. The target study population is a cohort of men who have sex with men (MSM) in the United States. Policy strategies considered include standard HIV prevention, daily oral PrEP, HIV…
This economic evaluation aims to support policy-making on the combined use of pre-exposure prophylaxis (PrEP) with HIV vaccines in development by evaluating the potential cost-effectiveness of implementation that would support the design of clinical trials for the assessment of combined product safety and efficacy. The target study population is a cohort of men who have sex with men (MSM) in the United States. Policy strategies considered include standard HIV prevention, daily oral PrEP, HIV vaccine, and their combination. We constructed a Markov model based on clinical trial data and the published literature. We used a payer perspective, monthly cycle length, a lifetime horizon, and a 3% discount rate. We assumed a price of $500 per HIV vaccine series in the base case. HIV vaccines dominated standard care and PrEP. At current prices, PrEP was not cost-effective alone or in combination. A combination strategy had the greatest health benefit but was not cost-effective (ICER = $463,448/QALY) as compared to vaccination alone. Sensitivity analyses suggest a combination may be valuable for higher-risk men with good adherence. Vaccine durability and PrEP drug prices were key drivers of cost-effectiveness. The results suggest that boosting potential may be key to HIV vaccine value.
Other authorsSee publication -
The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review
PharmacoEconomics - Open
-
A New Model for Catalyzing Translational Science: The Early Stage Investigator Mentored Research Scholar Program in HIV Vaccines
Clinical and Translational Science
Abstract
Engagement of early stage investigators (ESIs) in the search for a safe and effective vaccine is critical to the success of this highly challenging endeavor. In the wake of disappointing results from a large-scale efficacy trial, the HIV Vaccine Trials Network (HVTN) and Center for HIV/AIDS Vaccine Immunology (CHAVI) developed a novel mentored research program focused on the translation of findings from nonhuman primate studies to human trials of experimental vaccines. From 2008 to…Abstract
Engagement of early stage investigators (ESIs) in the search for a safe and effective vaccine is critical to the success of this highly challenging endeavor. In the wake of disappointing results from a large-scale efficacy trial, the HIV Vaccine Trials Network (HVTN) and Center for HIV/AIDS Vaccine Immunology (CHAVI) developed a novel mentored research program focused on the translation of findings from nonhuman primate studies to human trials of experimental vaccines. From 2008 to 2011, 14 ESI Scholars were selected from 42 complete applications. Post program surveys and tracked outcomes suggest that the combination of flexible funding, transdisciplinary mentorship, and structured training and networking promoted the scientific contributions and career development of promising ESIs. Embedding a multicomponent research program within collaborative clinical trial networks and research consortia is a promising strategy to attract and retain early career investigators and catalyze important translational science.Other authors -
Enhancing Diversity in the Public Health Research Workforce: The Research and Mentorship Program for Future HIV Vaccine Scientists
American Journal of Public Health
Abstract
Objectives. We developed and evaluated a novel National Institutes of Health-sponsored Research and Mentorship Program for African American and Hispanic medical students embedded within the international, multisite HIV Vaccine Trials Network, and explored its impact on scientific knowledge, acquired skills, and future career plans. Methods. Scholars conducted social, behavioral, clinical, or laboratory-based research projects with HIV Vaccine Trials Network investigators over 8 to…Abstract
Objectives. We developed and evaluated a novel National Institutes of Health-sponsored Research and Mentorship Program for African American and Hispanic medical students embedded within the international, multisite HIV Vaccine Trials Network, and explored its impact on scientific knowledge, acquired skills, and future career plans. Methods. Scholars conducted social, behavioral, clinical, or laboratory-based research projects with HIV Vaccine Trials Network investigators over 8 to 16 weeks (track 1) or 9 to 12 months (track 2). We conducted an in-depth, mixed-methods evaluation of the first 2 cohorts (2011-2013) to identify program strengths, areas for improvement, and influence on professional development. Results. A pre-post program assessment demonstrated increases in self-reported knowledge, professional skills, and interest in future HIV vaccine research. During in-depth interviews, scholars reported that a supportive, centrally administered program; available funding; and highly involved mentors and staff were keys to the program's early success. Conclusions. A multicomponent, mentored research experience that engages medical students from underrepresented communities and is organized within a clinical trials network may expand the pool of diverse public health scientists. Efforts to sustain scholar interest over time and track career trajectories are warranted. (Am J Public Health. Published online ahead of print August 14, 2014: e1-e8. doi:10.2105/AJPH.2014.302076).Other authors
Patents
Honors & Awards
-
Top 30 Leaders Changing Healthcare
Business Insider
https://www.businessinsider.com/30-people-under-40-changing-healthcare-2019-7
-
US Delegate to the Lindau Nobel Laureate Meeting on Economic Sciences
Lindau Nobel Laureate Committee
Invited to meet with Nobel Laureates in Economics during a 5-day meeting in Lindau, Germany. Supported by the National Science Foundation.
-
Davis Wright Tremaine Most Innovative Award
Buerk Center for Entrepreneurship
Awarded at the Science and Technology Showcase, hosted by the Buerk Center for Entrepreneurship, for co-founding of the SmartDx diagnostic platform for infectious diseases.
-
Pre-Doctoral Fellowship in Pharmaceutical Sciences
American Foundation for Pharmaceutical Education
More activity by Blythe
-
🌟 Calling all health economics experts 🌟 If you’re passionate about improving maternal and newborn outcomes, we want you on our team! 🔎 About…
🌟 Calling all health economics experts 🌟 If you’re passionate about improving maternal and newborn outcomes, we want you on our team! 🔎 About…
Liked by Blythe Adamson, PhD, MPH
-
This explains my motivation for spending the summer in Japan and Germany. The data is beautiful.
This explains my motivation for spending the summer in Japan and Germany. The data is beautiful.
Shared by Blythe Adamson, PhD, MPH
-
A new report, recently published by an ISPOR Task Force including Flatiron’s Blythe Adamson, PhD, MPH and other industry experts, provides actionable…
A new report, recently published by an ISPOR Task Force including Flatiron’s Blythe Adamson, PhD, MPH and other industry experts, provides actionable…
Liked by Blythe Adamson, PhD, MPH
-
For my fellow #breastcancer researchers out there, wanting to discuss the use of #AI in trials and clinical practice, join me at this event hosted by…
For my fellow #breastcancer researchers out there, wanting to discuss the use of #AI in trials and clinical practice, join me at this event hosted by…
Shared by Blythe Adamson, PhD, MPH
-
Thrilled to announce that my paper with Lou Garrison on incorporating real option value (ROV) is now published in a special supplement of…
Thrilled to announce that my paper with Lou Garrison on incorporating real option value (ROV) is now published in a special supplement of…
Liked by Blythe Adamson, PhD, MPH
-
Here are Good Practices with a #SUITABILITY data quality checklist to use EHR for comparative-effectiveness research and HTA
Here are Good Practices with a #SUITABILITY data quality checklist to use EHR for comparative-effectiveness research and HTA
Shared by Blythe Adamson, PhD, MPH
-
1 in 10 babies born in the US today will start their life in the NICU. We are doing everything in our power to change that at Pomelo Care. Today, we…
1 in 10 babies born in the US today will start their life in the NICU. We are doing everything in our power to change that at Pomelo Care. Today, we…
Liked by Blythe Adamson, PhD, MPH
-
Passed my PhD viva/oral defense today! I’m deeply grateful to my incredible supervisors, Professor Nick Latimer and Professor Jim Chilcott, whose…
Passed my PhD viva/oral defense today! I’m deeply grateful to my incredible supervisors, Professor Nick Latimer and Professor Jim Chilcott, whose…
Liked by Blythe Adamson, PhD, MPH
-
New National Bureau of Economic Research Working Paper alert on establishing the optimal share of surplus transfer by a social payer to an innovator…
New National Bureau of Economic Research Working Paper alert on establishing the optimal share of surplus transfer by a social payer to an innovator…
Liked by Blythe Adamson, PhD, MPH
-
Just wrapped an issue panel recording with Wim Goettsch, Joshua Ray, and Seamus Kent for #HTAi2024Seville! Exciting news - the session will be…
Just wrapped an issue panel recording with Wim Goettsch, Joshua Ray, and Seamus Kent for #HTAi2024Seville! Exciting news - the session will be…
Shared by Blythe Adamson, PhD, MPH
-
#ISPORAnnual New Professionals and Students - lets chat about career transitions, purposeful decision making, and pitfalls of navigating a career in…
#ISPORAnnual New Professionals and Students - lets chat about career transitions, purposeful decision making, and pitfalls of navigating a career in…
Liked by Blythe Adamson, PhD, MPH
-
Great to see the Frontiers e-book on the in the featured research topic "Novel methods and technologies for the evaluation of drug outcomes and…
Great to see the Frontiers e-book on the in the featured research topic "Novel methods and technologies for the evaluation of drug outcomes and…
Liked by Blythe Adamson, PhD, MPH
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More